Ownership Change to Note: Cytokinetics Inc Institutional Investor Sentiment Improved in Q3 2016
Cytokinetics Inc (NASDAQ:CYTK) institutional sentiment increased to 1.16 in 2016 Q3. Its up 0.70, from 0.46 in 2016Q2. The ratio improved, as 43 hedge funds opened new and increased equity positions, while 37 sold and decreased equity positions in Cytokinetics Inc. The hedge funds in our partner’s database now hold: 26.51 million shares, up from 26.30 million shares in 2016Q2. Also, the number of hedge funds holding Cytokinetics Inc in their top 10 equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 18 Reduced: 19 Increased: 30 New Position: 13.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The company has a market cap of $435.78 million. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It currently has negative earnings. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
The stock closed at $11 during the last session. It is down 44.55% since May 11, 2016 and is uptrending. It has outperformed by 34.51% the S&P500.
Analysts await Cytokinetics, Inc. (NASDAQ:CYTK) to report earnings on February, 21. They expect $-0.33 EPS, down 37.50% or $0.09 from last year’s $-0.24 per share. After $0.74 actual EPS reported by Cytokinetics, Inc. for the previous quarter, Wall Street now forecasts -144.59% negative EPS growth.
According to Zacks Investment Research, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.”
Bvf Inc Il holds 8.64% of its portfolio in Cytokinetics, Inc. for 5.00 million shares. Ecor1 Capital Llc owns 846,654 shares or 2.38% of their US portfolio. Moreover, Healthcare Value Capital Llc has 1.45% invested in the company for 100,000 shares. The California-based Dafna Capital Management Llc has invested 1.16% in the stock. Ironwood Investment Management Llc, a Massachusetts-based fund reported 133,509 shares.#img1#
Cytokinetics, Inc. (NASDAQ:CYTK) Ratings Coverage
Ratings analysis reveals 100% of Cytokinetics’s analysts are positive. Out of 6 Wall Street analysts rating Cytokinetics, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $14 while the high is $24. The stock’s average target of $18.83 is 71.18% above today’s ($11) share price. CYTK was included in 6 notes of analysts from July 24, 2015. The stock of Cytokinetics, Inc. (NASDAQ:CYTK) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The rating was maintained by FBR Capital with “Outperform” on Tuesday, November 10. The rating was maintained by MLV on Friday, July 24 with “Buy”. On Monday, November 9 the stock rating was maintained by Roth Capital with “Buy”. The stock of Cytokinetics, Inc. (NASDAQ:CYTK) earned “Buy” rating by Needham on Wednesday, July 27. The stock of Cytokinetics, Inc. (NASDAQ:CYTK) has “Buy” rating given on Monday, November 9 by TH Capital.
CYTK Company Profile
Cytokinetics, Incorporated, incorporated on August 5, 1997, is a late-stage biopharmaceutical company. The Firm is focused on discovering, developing and commercializing first-in-class muscle kmspico 10.0.4 activator download as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Firm is developing small molecule drug candidates, which are specifically engineered to increase muscle function and contractility. The Company’s drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil.
More important recent Cytokinetics, Inc. (NASDAQ:CYTK) news were published by: Globenewswire.com which released: “Cytokinetics, Inc. Reports Third Quarter 2016 Financial Results” on October 27, 2016, also Fool.com published article titled: “Why Cytokinetics, Inc. Got Hammered Today”, Globenewswire.com published: “Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results” on July 28, 2016. More interesting news about Cytokinetics, Inc. (NASDAQ:CYTK) was released by: Finance.Yahoo.com and their article: “Cytokinetics to Participate in Upcoming Investor Conferences” with publication date: November 22, 2016.
Cytokinetics Inc.-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
via source:http://www.kentuckypostnews.com/2016/12/14/ownership-change-to-note-cytokinetics-inc-institutional-investor-sentiment-improved-in-q3-2016/

















